• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Fate Therapeutics, Inc. - Common Stock (NQ:FATE)

2.010 -0.050 (-2.43%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 15, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Fate Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
News headline image
Fate Therapeutics Announces Leadership Transition
November 29, 2024
From Fate Therapeutics, Inc.
Via GlobeNewswire
News headline image
Iris Energy, Arrowhead Pharmaceuticals, Urban Outfitters And Other Big Stocks Moving Higher On Wednesday ↗
November 27, 2024
U.S. stocks were lower, with the Dow Jones index falling more than 100 points on Wednesday. 
Via Benzinga
Topics Stocks
News headline image
Fate Therapeutics to Present at Upcoming December Investor Conferences
November 26, 2024
From Fate Therapeutics, Inc.
Via GlobeNewswire
News headline image
Fate Therapeutics Presents 6-Month Follow-up Data on First Patient Treated in Phase 1 Autoimmunity Study with Fludarabine-free Conditioning and FT819 Off-the-shelf, 1XX CAR T-cell Product Candidate at ACR Convergence
November 18, 2024
From Fate Therapeutics, Inc.
Via GlobeNewswire
News headline image
Expert Outlook: Fate Therapeutics Through The Eyes Of 9 Analysts ↗
June 17, 2024
 
Via Benzinga
News headline image
Forecasting The Future: 8 Analyst Projections For Fate Therapeutics ↗
May 06, 2024
 
Via Benzinga
News headline image
Fate Therapeutics Highlights FT522 Off-the-shelf, ADR-armed CAR NK Cell Product Candidate at 2024 ACR Convergence
November 18, 2024
From Fate Therapeutics, Inc.
Via GlobeNewswire
News headline image
Fate Therapeutics Reports Third Quarter 2024 Financial Results and Business Updates
November 12, 2024
From Fate Therapeutics, Inc.
Via GlobeNewswire
News headline image
Fate Therapeutics Highlights Cancer-selective, HER2-Targeting Profile of FT825 / ONO-8250 CAR T-cell Product Candidate for Treatment of Advanced Solid Tumors at 2024 SITC Annual Meeting
November 09, 2024
From Fate Therapeutics, Inc.
Via GlobeNewswire
News headline image
Fate Therapeutics Presents Pan-tumor Targeting Preclinical Data for FT836 MICA/B-targeted CAR T-cell Product Candidate at 2024 SITC Annual Meeting
November 08, 2024
From Fate Therapeutics, Inc.
Via GlobeNewswire
News headline image
Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
November 04, 2024
From Fate Therapeutics, Inc.
Via GlobeNewswire
News headline image
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
October 02, 2024
From Fate Therapeutics, Inc.
Via GlobeNewswire
News headline image
Fate Therapeutics to Present at 2024 Cantor Global Healthcare Conference
September 12, 2024
From Fate Therapeutics, Inc.
Via GlobeNewswire
News headline image
FATE Stock Earnings: Fate Therapeutics Beats EPS, Beats Revenue for Q2 2024 ↗
August 13, 2024
FATE stock results show that Fate Therapeutics beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. 
Via InvestorPlace
News headline image
Fate Therapeutics Reports Second Quarter 2024 Financial Results and Business Updates
August 13, 2024
From Fate Therapeutics, Inc.
Via GlobeNewswire
News headline image
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
August 02, 2024
From Fate Therapeutics, Inc.
Via GlobeNewswire
News headline image
Fate Therapeutics Appoints Neely Mozaffarian, MD, PhD, FACR, to its Board of Directors
July 31, 2024
From Fate Therapeutics, Inc.
Via GlobeNewswire
News headline image
Billionaires Are Buying These 2 Beaten-Down Stocks. Are They Smart Buys for Your Portfolio? ↗
July 21, 2024
The Baker brothers are billionaires with a successful track record in the biopharmaceutical industry. 
Via The Motley Fool
News headline image
Why Charles Schwab Shares Are Trading Lower By Over 7%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗
July 16, 2024
 
Via Benzinga
News headline image
UnitedHealth Posts Better-Than-Expected Earnings, Joins AngioDynamics, Bank of America And Other Big Stocks Moving Higher On Tuesday ↗
July 16, 2024
 
Via Benzinga
News headline image
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
July 02, 2024
From Fate Therapeutics, Inc.
Via GlobeNewswire
News headline image
This Best Buy Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday ↗
June 17, 2024
 
Via Benzinga
News headline image
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
June 04, 2024
From Fate Therapeutics, Inc.
Via GlobeNewswire
News headline image
Fate Therapeutics to Present at 2024 Jefferies Global Healthcare Conference
May 29, 2024
From Fate Therapeutics, Inc.
Via GlobeNewswire
News headline image
Alibaba To Rally Over 13%? Here Are 10 Top Analyst Forecasts For Thursday ↗
May 16, 2024
 
Via Benzinga
News headline image
FATE Stock Earnings: Fate Therapeutics Beats EPS, Beats Revenue for Q1 2024 ↗
May 09, 2024
FATE stock results show that Fate Therapeutics beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. 
Via InvestorPlace
News headline image
Fate Therapeutics Reports First Quarter 2024 Financial Results and Business Updates
May 09, 2024
From Fate Therapeutics, Inc.
Via GlobeNewswire
News headline image
Fate Therapeutics Announces First Lupus Patient Treated in Phase 1 Autoimmunity Study of Off-the-shelf FT819 CAR T-cell Program
May 09, 2024
From Fate Therapeutics, Inc.
Via GlobeNewswire
News headline image
Fate Therapeutics to Webcast Conference Call Reporting First Quarter 2024 Financial Results and Operational Updates
May 06, 2024
From Fate Therapeutics, Inc.
Via GlobeNewswire
News headline image
Fate Therapeutics Announces Presentation of FT522 Preclinical Data for Autoimmune Diseases in Late-breaking Abstract at ASGCT Annual Meeting
May 03, 2024
From Fate Therapeutics, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap